Teva Pharmaceutical Industries (TEVA) Amortization - Intangibles (2018 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Amortization - Intangibles for 9 consecutive years, with $8.0 million the latest figure, recorded in Q1 2026.

• Quarterly Amortization - Intangibles fell 93.39% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146.0 million (down 50.0% YoY) and the FY2025 annual result came in at $259.0 million, up 3.19% from the prior year.
• Amortization - Intangibles declined to $8.0 million in Q1 2026 per TEVA's latest filing, from $32.0 million in the prior quarter.
• Over the last five years, Amortization - Intangibles for TEVA reached as high as $178.0 million in Q1 2023 and fell as low as $8.0 million in Q1 2026.
• A 5-year average of $71.9 million and a median of $61.0 million in 2023 frame the typical range for Amortization - Intangibles.
• Annual changes were most pronounced in 2025 — Amortization - Intangibles soared 128.57% — and 2026, when it sank 93.39%.
• Year by year, Amortization - Intangibles stood at $132.0 million in 2022, then sank by 53.79% to $61.0 million in 2023, then surged by 34.43% to $82.0 million in 2024, then tumbled by 60.98% to $32.0 million in 2025, then tumbled by 75.0% to $8.0 million in 2026.
• According to Business Quant data, Amortization - Intangibles over the past three periods registered $8.0 million, $32.0 million, and $64.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.